Agenus to Present Clinical Data on Lead Programs at ASCO 2018

May 17, 2018

- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses

- More than 100 patients treated with AGEN1884 and AGEN2034

- Combination trial has commenced in cervical cancer

LEXINGTON, Mass., May 17**,** 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies[1], announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) antibodies have shown consistent clinical activity with a number of partial responses, stable disease and currently, one complete responder. Updated data on these agents will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, in Chicago June 1-5. Agenus recently announced the launch of a combination study with AGEN1884 and AGEN2034 in second-line cervical cancer (NCT03495882), designed as a potential pivotal program to support a rapid path to BLA.

"Our strategy is built on innovation and speed, critical elements for success in I-O. Our lead CTLA-4 and PD-1 are advancing rapidly in the clinic with more than 100 patients treated," said Garo Armen, PhD, Chairman and CEO of Agenus. "AGEN1884 is the most advanced anti-CTLA-4 antibody (of the same IgG1 subclass as Yervoy®) in the clinic with the potential to be the second to market. We are pleased to report that after the first 100 patients have been treated, our antibodies are clinically active and are advancing in combination in second-line cervical cancer, an indication for which patients have no effective therapies, and presents a path to BLA filing."

Poster Presentation Details:

- Clinical data from AGEN2034 trial

Poster Title: Phase 1/2 Open-Label, Multiple Ascending Dose Trial of AGEN2034, an anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation

Session: Developmental Therapeutics—Immunotherapy
Abstract Number: 3086
Poster Board Number: 300
Session Date: Monday, June 4, 2018
Location: Hall A
Session Time: 8:00 AM to 11:30 AM

- Clinical data from AGEN1884 trial

Poster Title: Phase 1 Open-Label, Ascending Dose Trial of AGEN1884, an anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade

Session: Developmental Therapeutics—Immunotherapy
Abstract Number: 3075
Poster Board Number: 289
Session Date: Monday, June 4, 2018
Location: Hall A
Session Time: 8:00 AM to 11:30 AM

At ASCO, Agenus will provide an update on the specifics of clinical responses as well as pharmacologic and pharmacodynamic responses of AGEN1884 and AGEN2034 in patients with advanced and refractory solid tumors. Data from the combination study will be presented at future medical meetings.

Abstracts and posters will become available on the Company's website at http://agenusbio.com/technology/publications/ following the poster sessions.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite

of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' planned presentations of clinical data at ASCO, the planned presentation of additional data at future medical meetings, the potential for AGEN1884 to be the second-to-market CTLA-4 antibody, the potential for Agenus' combination trial in second-line cervical cancer to be a pivotal trial with a rapid path to BLA, and other clinical trial plans and activities. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

[1]Through AgenTus Therapeutics, a subsidiary of Agenus

SOURCE Agenus Inc.